0001905252-22-000001.txt : 20220121 0001905252-22-000001.hdr.sgml : 20220121 20220121134142 ACCESSION NUMBER: 0001905252-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220121 DATE AS OF CHANGE: 20220121 EFFECTIVENESS DATE: 20220121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solve Therapeutics, Inc. CENTRAL INDEX KEY: 0001905252 IRS NUMBER: 863795367 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-430372 FILM NUMBER: 22545308 BUSINESS ADDRESS: STREET 1: 1025 ALAMEDA DE LAS PULGAS, SUITE 122 CITY: BELMONT STATE: CA ZIP: 94002 BUSINESS PHONE: (858) 357-4137 MAIL ADDRESS: STREET 1: 1025 ALAMEDA DE LAS PULGAS, SUITE 122 CITY: BELMONT STATE: CA ZIP: 94002 D 1 primary_doc.xml X0708 D LIVE 0001905252 Solve Therapeutics, Inc. 1025 ALAMEDA DE LAS PULGAS, SUITE 122 BELMONT CA CALIFORNIA 94002 (858) 357-4137 DELAWARE None None Corporation true 2021 David Johnson c/o Solve Therapeutics, Inc. 1025 Alameda De Las Pulgas, Suite 122 Belmont CA CALIFORNIA 94002 Executive Officer Director Peter Colabuono c/o Solve Therapeutics, Inc. 1025 Alameda De Las Pulgas, Suite 122 Belmont CA CALIFORNIA 94002 Director Alan Colowick c/o Solve Therapeutics, Inc. 1025 Alameda De Las Pulgas, Suite 122 Belmont CA CALIFORNIA 94002 Director Langdon Miller c/o Solve Therapeutics, Inc. 1025 Alameda De Las Pulgas, Suite 122 Belmont CA CALIFORNIA 94002 Executive Officer Biotechnology Decline to Disclose 06b false 2021-12-17 false true false 0 126510820 63510835 62999985 false 11 0 0 0 false Solve Therapeutics, Inc. /s/David Johnson David Johnson President and Chief Executive Officer 2022-01-21